Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verrica Pharmaceuticals Inc.

0.5373
-0.0538-9.10%
Post-market: 0.54680.0095+1.77%18:33 EDT
Volume:391.17K
Turnover:219.20K
Market Cap:49.31M
PE:-0.36
High:0.5900
Open:0.5804
Low:0.5370
Close:0.5911
Loading ...

Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

GuruFocus.com
·
12 Mar

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
12 Mar

Verrica Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

Verrica Pharmaceuticals Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing

THOMSON REUTERS
·
12 Mar

Verrica Pharmaceuticals Q4 2024 Adj. EPS $(0.18) Beats $(0.26) Estimate, Sales $344.000K Miss $1.041M Estimate

Benzinga
·
12 Mar

Corrected-Verrica Pharmaceuticals Q4 Collaboration Revenue USD 29 Thousand (Corrects Amount)

THOMSON REUTERS
·
12 Mar

Verrica Pharmaceuticals Q4 Basic EPS USD -0.24

THOMSON REUTERS
·
12 Mar

Verrica Pharmaceuticals Q4 Collaboration Revenue USD 315 Thousand

THOMSON REUTERS
·
12 Mar

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
12 Mar

Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
07 Mar

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

GlobeNewswire
·
03 Mar

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
27 Feb

Verrica Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
24 Feb

Verrica Pharmaceuticals - Waiver Includes Requirements That There Be No 'Going Concern' Qualification for 2024 and Q1 2025

THOMSON REUTERS
·
22 Feb

Shareholders Can't Ignore US$1.1m Of Sales By Verrica Pharmaceuticals Insiders

Simply Wall St.
·
24 Jan

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of Vp-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

THOMSON REUTERS
·
21 Jan